Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Tables)

v3.24.3
Segment Information (Tables)
3 Months Ended
Sep. 30, 2024
Notes Tables  
Schedule of financial information by reportable segment

The following is financial information relating to the Company's reportable segments (in thousands):

​

​

​

​

​

​

​

​

​

​

Quarter Ended

​

​

September 30, 

​

    

2024

    

2023

Net sales:

 

​

  

​

​

​

Protein Sciences

​

$

204,535

  

$

204,655

Diagnostics and Spatial Biology

​

 

83,192

​

 

72,797

Other revenue(1)

​

​

2,303

​

​

—

Intersegment

​

 

(572)

​

 

(517)

Consolidated net sales

​

$

289,458

  

$

276,935

​

​

​

​

​

​

​

Operating income:

​

 

  

​

 

  

Protein Sciences

​

$

80,541

  

$

88,361

Diagnostics and Spatial Biology

​

 

4,277

​

 

527

Segment operating income

​

$

84,818

​

$

88,888

Costs recognized on sale of acquired inventory

​

 

(188)

​

 

(181)

Amortization of intangibles

​

 

(19,741)

​

 

(19,851)

Acquisition related expenses and other

​

 

(1,513)

​

 

588

Certain litigation charges

​

​

(292)

​

​

—

Stock based compensation, inclusive of employer taxes

​

 

(10,637)

​

 

(11,494)

Restructuring and restructuring-related costs

​

 

(11,022)

​

 

(89)

Corporate general, selling, and administrative expenses

​

 

(1,586)

​

 

(1,999)

Impact of business held-for-sale(1)

​

​

148

​

​

—

Consolidated operating income

​

$

39,987

  

$

55,862

​

(1) Includes the quarterly results of a business that has met the held-for-sale criteria since December 31, 2023.